SLN
Silence Therapeutics Plc - ADR

371
Loading...
Loading...
News
all
press releases
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Zacks·3mo ago
News Placeholder
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Zacks·4mo ago
News Placeholder
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release...
Business Wire·7mo ago
News Placeholder
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics plc (Silence or the Company) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the...
Business Wire·9mo ago
News Placeholder
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical stage biotechnology company committed to transforming peoples lives by silencing diseases through precision...
Business Wire·10mo ago
News Placeholder
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. read more...
Benzinga·10mo ago
News Placeholder
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical stage biotechnology company committed to transforming peoples lives by silencing diseases through precision...
Business Wire·10mo ago
News Placeholder
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
read more...
Benzinga·10mo ago
News Placeholder
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical stage biotechnology company committed to transforming peoples lives by silencing diseases through precision...
Business Wire·10mo ago

Latest SLN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.